FOGLI, STEFANO Statistiche
FOGLI, STEFANO
DIPARTIMENTO DI MEDICINA CLINICA E SPERIMENTALE
Expression of Circulating let-7e and miR-126 May Predict Clinical Remission in Patients With Crohn's Disease Treated With Anti-TNF-α Biologics
2023-01-01 Guglielmi, Giorgio; Crucitta, Stefania; Bertani, Lorenzo; Ruglioni, Martina; Svizzero, Giovanni Baiano; Ceccarelli, Linda; Del Re, Marzia; Danesi, Romano; Costa, Francesco; Fogli, Stefano
Multidisciplinary management of HER2-positive breast cancer with brain metastases: An evidence-based pragmatic approach moving from pathophysiology to clinical data
2023-01-01 Giordano, Guido; Griguolo, Gaia; Landriscina, Matteo; Meattini, Icro; Carbone, Francesco; Leone, Augusto; Del Re, Marzia; Fogli, Stefano; Danesi, Romano; Colamaria, Antonio; Dieci, Maria Vittoria
Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib
2022-01-01 Del Re, Marzia; Crucitta, Stefania; Omarini, Claudia; Bargagna, Irene; Mongillo, Marta; Palleschi, Michela; Stucci, Stefania; Meattini, Icro; D'Onofrio, Raffaella; Lorenzini, Giulia; Biondani, Pamela; De Giorgi, Ugo; Porta, Camillo; Livi, Lorenzo; Natalizio, Salvatore; Fontana, Andrea; Giontella, Elena; Angelini, Lucia; Fogli, Stefano; Danesi, Romano
Corticosteroids in oncology: Use, overuse, indications, contraindications. An Italian Association of Medical Oncology (AIOM)/ Italian Association of Medical Diabetologists (AMD)/ Italian Society of Endocrinology (SIE)/ Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper
2022-01-01 Faggiano, A.; Mazzilli, R.; Natalicchio, A.; Adinolfi, V.; Argentiero, A.; Danesi, R.; D'Oronzo, S.; Fogli, S.; Gallo, M.; Giuffrida, D.; Gori, S.; Montagnani, M.; Ragni, A.; Renzelli, V.; Russo, A.; Silvestris, N.; Franchina, T.; Tuveri, E.; Cinieri, S.; Colao, A.; Giorgino, F.; Zatelli, M. C.
Diagnosis and treatment monitoring in breast cancer: how liquid biopsy can support patient management
2022-01-01 Cucchiara, Federico; Scarpitta, Rosa; Crucitta, Stefania; Scatena, Cristian; Arici, Roberta; Naccarato, Antonio Giuseppe; Fogli, Stefano; Danesi, Romano; Del Re, Marzia
Reply to comments on: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients
2022-01-01 Del Re, M.; Omarini, C.; Diodati, L.; Palleschi, M.; Meattini, I.; Crucitta, S.; Lorenzini, G.; Isca, C.; Fontana, A.; Livi, L.; Piacentini, F.; Fogli, S.; De Giorgi, U.; Danesi, R.
The expanding family of c-Met inhibitors in solid tumors: a comparative analysis of their pharmacologic and clinical differences
2022-01-01 Fogli, Stefano; Tabbò, Fabrizio; Capuano, Annalisa; DEL RE, Marzia; Passiglia, Francesco; Cucchiara, Federico; Scavone, Cristina; Gori, Veronica; Novello, Silvia; Schmidinger, Manuela; Danesi, Romano
Blood-based PD-L1 analysis in tumor-derived extracellular vesicles: Applications for optimal use of anti-PD-1/PD-L1 axis inhibitors
2021-01-01 Del Re, M.; van Schaik, R. H. N.; Fogli, S.; Mathijssen, R. H. J.; Cucchiara, F.; Capuano, A.; Scavone, C.; Jenster, G. W.; Danesi, R.
Clinical pharmacology and drug-drug interactions of lenvatinib in thyroid cancer
2021-01-01 Fogli, S.; Gianfilippo, G.; Cucchiara, F.; Del Re, M.; Valerio, L.; Elisei, R.; Danesi, R.
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients
2021-01-01 Del Re, M.; Omarini, C.; Diodati, L.; Palleschi, M.; Meattini, I.; Crucitta, S.; Lorenzini, G.; Isca, C.; Fontana, A.; Livi, L.; Piacentini, F.; Fogli, S.; De Giorgi, U.; Danesi, R.
Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor Boards
2021-01-01 Danesi, R; Fogli, S; Indraccolo, S; Del Re, M; Dei Tos, A P; Leoncini, L; Antonuzzo, L; Bonanno, L; Guarneri, V; Pierini, A; Amunni, G; Conte, P
Gemcitabine plus nab-paclitaxel induces PD-L1 mRNA expression in plasma-derived microvesicles in pancreatic cancer
2021-01-01 Del Re, M.; Vivaldi, C.; Rofi, E.; Salani, F.; Crucitta, S.; Catanese, S.; Fontanelli, L.; Massa, V.; Cucchiara, F.; Fornaro, L.; Capuano, A.; Fogli, S.; Vasile, E.; Danesi, R.
Pharmacological Basis of Breast Cancer Resistance to Therapies - An Overview
2021-01-01 Crucitta, Stefania; Cucchiara, Federico; Sciandra, Francesca; Cerbioni, Annalisa; Diodati, Lucrezia; Rafaniello, Concetta; Capuano, Annalisa; Fontana, Andrea; Fogli, Stefano; Danesi, Romano; DEL RE, Marzia
Pharmacology differences among proteasome inhibitors: Implications for their use in clinical practice
2021-01-01 Fogli, S.; Galimberti, S.; Gori, V.; Del Re, M.; Danesi, R.
Circulating microRNAs as biomarkers for early diagnosis of cutaneous melanoma
2020-01-01 Carpi, Sara; Polini, Beatrice; Fogli, Stefano; Podestà, Adriano; Ylösmäki, Erkko; Cerullo, Vincenzo; Romanini, Antonella; Nieri, Paola
ErbB in NSCLC as a molecular target: Current evidences and future directions
2020-01-01 Del Re, M.; Cucchiara, F.; Petrini, I.; Fogli, S.; Passaro, A.; Crucitta, S.; Attili, I.; De Marinis, F.; Chella, A.; Danesi, R.
Erratum: Clinical pharmacology of monoclonal antibodies targeting PD-1 axis in urothelial cancers
2020-01-01 Rofi, E.; Del Re, M.; Arrigoni, E.; Rizzo, M.; Fontanelli, L.; Crucitta, S.; Gianfilippo, G.; Restante, G.; Fogli, S.; Porta, C.; Danesi, R.; Schmidinger, M.
Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs
2020-01-01 Fogli, Stefano; Porta, Camillo; Del Re, Marzia; Crucitta, Stefania; Gianfilippo, Giulia; Danesi, Romano; Rini, Brian I; Schmidinger, Manuela
Response to Wirostko et al. Re: "Cross-Linked Hyaluronic Acid as Tear Film Substitute" by Posarelli et al. (J Ocul Pharmacol Ther 2019;35(7):381-387)
2020-01-01 Posarelli, C.; Passani, A.; Del Re, M.; Fogli, S.; Toro, M. D.; Ferreras, A.; Figus, M.
Clinical pharmacology of monoclonal antibodies targeting anti-PD-1 axis in urothelial cancers
2019-01-01 Rofi, E.; Del Re, M.; Arrigoni, E.; Rizzo, M.; Fontanelli, L.; Crucitta, S.; Gianfilippo, G.; Restante, G.; Fogli, S.; Porta, C.; Danesi, R.; Schmidinger, M.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Expression of Circulating let-7e and miR-126 May Predict Clinical Remission in Patients With Crohn's Disease Treated With Anti-TNF-α Biologics | 1-gen-2023 | Guglielmi, Giorgio; Crucitta, Stefania; Bertani, Lorenzo; Ruglioni, Martina; Svizzero, Giovanni Baiano; Ceccarelli, Linda; Del Re, Marzia; Danesi, Romano; Costa, Francesco; Fogli, Stefano | |
| Multidisciplinary management of HER2-positive breast cancer with brain metastases: An evidence-based pragmatic approach moving from pathophysiology to clinical data | 1-gen-2023 | Giordano, Guido; Griguolo, Gaia; Landriscina, Matteo; Meattini, Icro; Carbone, Francesco; Leone, Augusto; Del Re, Marzia; Fogli, Stefano; Danesi, Romano; Colamaria, Antonio; Dieci, Maria Vittoria | |
| Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib | 1-gen-2022 | Del Re, Marzia; Crucitta, Stefania; Omarini, Claudia; Bargagna, Irene; Mongillo, Marta; Palleschi, Michela; Stucci, Stefania; Meattini, Icro; D'Onofrio, Raffaella; Lorenzini, Giulia; Biondani, Pamela; De Giorgi, Ugo; Porta, Camillo; Livi, Lorenzo; Natalizio, Salvatore; Fontana, Andrea; Giontella, Elena; Angelini, Lucia; Fogli, Stefano; Danesi, Romano | |
| Corticosteroids in oncology: Use, overuse, indications, contraindications. An Italian Association of Medical Oncology (AIOM)/ Italian Association of Medical Diabetologists (AMD)/ Italian Society of Endocrinology (SIE)/ Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper | 1-gen-2022 | Faggiano, A.; Mazzilli, R.; Natalicchio, A.; Adinolfi, V.; Argentiero, A.; Danesi, R.; D'Oronzo, S.; Fogli, S.; Gallo, M.; Giuffrida, D.; Gori, S.; Montagnani, M.; Ragni, A.; Renzelli, V.; Russo, A.; Silvestris, N.; Franchina, T.; Tuveri, E.; Cinieri, S.; Colao, A.; Giorgino, F.; Zatelli, M. C. | |
| Diagnosis and treatment monitoring in breast cancer: how liquid biopsy can support patient management | 1-gen-2022 | Cucchiara, Federico; Scarpitta, Rosa; Crucitta, Stefania; Scatena, Cristian; Arici, Roberta; Naccarato, Antonio Giuseppe; Fogli, Stefano; Danesi, Romano; Del Re, Marzia | |
| Reply to comments on: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients | 1-gen-2022 | Del Re, M.; Omarini, C.; Diodati, L.; Palleschi, M.; Meattini, I.; Crucitta, S.; Lorenzini, G.; Isca, C.; Fontana, A.; Livi, L.; Piacentini, F.; Fogli, S.; De Giorgi, U.; Danesi, R. | |
| The expanding family of c-Met inhibitors in solid tumors: a comparative analysis of their pharmacologic and clinical differences | 1-gen-2022 | Fogli, Stefano; Tabbò, Fabrizio; Capuano, Annalisa; DEL RE, Marzia; Passiglia, Francesco; Cucchiara, Federico; Scavone, Cristina; Gori, Veronica; Novello, Silvia; Schmidinger, Manuela; Danesi, Romano | |
| Blood-based PD-L1 analysis in tumor-derived extracellular vesicles: Applications for optimal use of anti-PD-1/PD-L1 axis inhibitors | 1-gen-2021 | Del Re, M.; van Schaik, R. H. N.; Fogli, S.; Mathijssen, R. H. J.; Cucchiara, F.; Capuano, A.; Scavone, C.; Jenster, G. W.; Danesi, R. | |
| Clinical pharmacology and drug-drug interactions of lenvatinib in thyroid cancer | 1-gen-2021 | Fogli, S.; Gianfilippo, G.; Cucchiara, F.; Del Re, M.; Valerio, L.; Elisei, R.; Danesi, R. | |
| Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients | 1-gen-2021 | Del Re, M.; Omarini, C.; Diodati, L.; Palleschi, M.; Meattini, I.; Crucitta, S.; Lorenzini, G.; Isca, C.; Fontana, A.; Livi, L.; Piacentini, F.; Fogli, S.; De Giorgi, U.; Danesi, R. | |
| Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor Boards | 1-gen-2021 | Danesi, R; Fogli, S; Indraccolo, S; Del Re, M; Dei Tos, A P; Leoncini, L; Antonuzzo, L; Bonanno, L; Guarneri, V; Pierini, A; Amunni, G; Conte, P | |
| Gemcitabine plus nab-paclitaxel induces PD-L1 mRNA expression in plasma-derived microvesicles in pancreatic cancer | 1-gen-2021 | Del Re, M.; Vivaldi, C.; Rofi, E.; Salani, F.; Crucitta, S.; Catanese, S.; Fontanelli, L.; Massa, V.; Cucchiara, F.; Fornaro, L.; Capuano, A.; Fogli, S.; Vasile, E.; Danesi, R. | |
| Pharmacological Basis of Breast Cancer Resistance to Therapies - An Overview | 1-gen-2021 | Crucitta, Stefania; Cucchiara, Federico; Sciandra, Francesca; Cerbioni, Annalisa; Diodati, Lucrezia; Rafaniello, Concetta; Capuano, Annalisa; Fontana, Andrea; Fogli, Stefano; Danesi, Romano; DEL RE, Marzia | |
| Pharmacology differences among proteasome inhibitors: Implications for their use in clinical practice | 1-gen-2021 | Fogli, S.; Galimberti, S.; Gori, V.; Del Re, M.; Danesi, R. | |
| Circulating microRNAs as biomarkers for early diagnosis of cutaneous melanoma | 1-gen-2020 | Carpi, Sara; Polini, Beatrice; Fogli, Stefano; Podestà, Adriano; Ylösmäki, Erkko; Cerullo, Vincenzo; Romanini, Antonella; Nieri, Paola | |
| ErbB in NSCLC as a molecular target: Current evidences and future directions | 1-gen-2020 | Del Re, M.; Cucchiara, F.; Petrini, I.; Fogli, S.; Passaro, A.; Crucitta, S.; Attili, I.; De Marinis, F.; Chella, A.; Danesi, R. | |
| Erratum: Clinical pharmacology of monoclonal antibodies targeting PD-1 axis in urothelial cancers | 1-gen-2020 | Rofi, E.; Del Re, M.; Arrigoni, E.; Rizzo, M.; Fontanelli, L.; Crucitta, S.; Gianfilippo, G.; Restante, G.; Fogli, S.; Porta, C.; Danesi, R.; Schmidinger, M. | |
| Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs | 1-gen-2020 | Fogli, Stefano; Porta, Camillo; Del Re, Marzia; Crucitta, Stefania; Gianfilippo, Giulia; Danesi, Romano; Rini, Brian I; Schmidinger, Manuela | |
| Response to Wirostko et al. Re: "Cross-Linked Hyaluronic Acid as Tear Film Substitute" by Posarelli et al. (J Ocul Pharmacol Ther 2019;35(7):381-387) | 1-gen-2020 | Posarelli, C.; Passani, A.; Del Re, M.; Fogli, S.; Toro, M. D.; Ferreras, A.; Figus, M. | |
| Clinical pharmacology of monoclonal antibodies targeting anti-PD-1 axis in urothelial cancers | 1-gen-2019 | Rofi, E.; Del Re, M.; Arrigoni, E.; Rizzo, M.; Fontanelli, L.; Crucitta, S.; Gianfilippo, G.; Restante, G.; Fogli, S.; Porta, C.; Danesi, R.; Schmidinger, M. |